GeneDx Holdings A Aktie

GeneDx reported at the Wells Fargo healthcare conference a volume increase of 32% in Q2 2024, accelerated profitability and a gross margin of around 70%. New growth drivers are general pediatrics, prenatal and perinatal medicine, pediatric neurology and NICUs, while product innovation such as exome-to-genome reflex supports market position. A weakness remains receivables collection, with current collection rates of around 32–35%; management aims to raise this to about 70% in the medium term and expects noticeable improvements from Q4 2024. GeneDx has a $50 million credit facility, roughly $200 million pro-forma cash and sees continued high long-term growth potential alongside margin improvement. » Más en de.investing.com

GeneDx reports strong volume growth (up 32% year-to-date) and an earlier return to adjusted profitability, but confirms its 2026 revenue forecast of at least $475 million. Commercial insurance coverage for whole-genome sequencing rose to 88%, yet actual realized payments on insurance billings were only about 32%. Management sees the gap between volume and cash collections as the key operational challenge and is focused on improvements in the billing cycle, customer experience, product quality and capital discipline. The company expects material revenue effects from new reimbursement policies more likely in 2027 than at the end of 2026. » Más en de.investing.com

Prosight Management disclosed a purchase of 468,463 shares of GeneDx Holdings, an estimated $42.7 million addition that now represents about 5.51% of its reportable AUM. GeneDx reported Q1 revenue up 17% to $102.3 million and testing volume up 34% to 27,488 tests, and management still expects at least 30% exome and genome volume growth and roughly 70% adjusted gross margins for the year. The company lowered its full-year revenue guidance to $475–490 million from $540–555 million, and its shares are down about 30% over the past year. Prosight’s purchase signals confidence in GeneDx’s growing genomic database and AI-driven diagnostics despite the revised outlook. » Más en finance.yahoo.com